

Table of Contents

About the authors	2
Disclaimer	2
Executive summary	16
Introduction and methodology	16
Epidemiology and market intelligence	16
Deals intelligence	17
Profiles of the most promising licensing opportunities	18
Chapter 1 Introduction and methodology	19
Introduction	19
Citeline Drug Intelligence	19
Citeline’s TrialTrove	19
Datamonitor’s PharmaVitae Explorer	19
MedTRACK	20
Methodology	20
Overview	20
Details	20
Identification of candidates	20
Selection of the most promising licensing opportunities	21
Expert panel	22
Chapter 2 Epidemiology and market intelligence	24
Overview	24
Epidemiology	24
Type of cancers	24

Geographical distribution of cancer epidemiology	26
Treatments for cancer	28
Targeted therapies	30
Cancer vaccines	30
Combination treatments	30
Pricing of cancer drugs	31
Market size	31
Chapter 3 Deals intelligence	36
Trends in cancer licensing deals	36
Examples of recent deals in oncology	45
Chapter 4 Profiles of the most promising licensing opportunities	50
Drug	50
Overview	50
Clinical trials	51
Biomarkers	51
Comment	52
Drug	52
Overview	52
Clinical trials	54
Biomarkers	56
Comment	57
Drug	58
Overview	58
Clinical trials	59
Biomarkers	60

Comment	60
Drug	61
Overview	61
Clinical trials	62
Biomarkers	63
Comment	63
Drug	64
Overview	64
Clinical trials	65
Biomarkers	65
Comment	65
Drug	66
Overview	66
Clinical trials	67
Biomarkers	67
Comment	67
Drug	68
Overview	68
Clinical trials	69
Biomarkers	69
Comment	69
Drug	70
Overview	70
Clinical trials	71
Biomarkers	71
Comment	71
Drug	72

Overview	72
Clinical trials	73
Biomarkers	74
Comment	74
Drug	74
Overview	74
Clinical trials	75
Biomarkers	76
Comment	76
Drug	76
Overview	76
Clinical trials	78
Biomarkers	78
Comment	79
Drug	79
Overview	79
Clinical trials	80
Biomarkers	80
Comment	80
Drug	81
Overview	81
Clinical trials	82
Biomarkers	83
Comment	83
Drug	84
Overview	84
Clinical trials	84

Biomarkers	84
Comment	84
Drug	85
Overview	85
Clinical trials	87
Biomarkers	87
Comment	87
Drug	88
Overview	88
Clinical trials	89
Biomarkers	90
Comment	91
Drug	91
Overview	91
Clinical trials	92
Biomarkers	92
Comment	92
Drug	93
Overview	93
Clinical trials	94
Biomarkers	94
Comment	94
Drug	94
Overview	94
Clinical trials	96
Biomarkers	97
Comment	97

Drug	98
Overview	98
Clinical trials	99
Biomarkers	102
Comment	103
Drug	104
Overview	104
Clinical trials	105
Biomarkers	108
Comment	110
Drug	110
Overview	110
Clinical trials	111
Biomarkers	111
Comment	111
Drug	112
Overview	112
Clinical trials	113
Biomarkers	114
Comment	114
Drug	115
Overview	115
Clinical trials	116
Biomarkers	117
Comment	117
Drug	117
Overview	117

Clinical trials	119
Biomarkers	120
Comment	120
Drug	120
Overview	120
Clinical trials	121
Biomarkers	123
Comment	123
Drug	124
Overview	124
Clinical trials	125
Biomarkers	125
Comment	125
Drug	126
Overview	126
Clinical trials	127
Biomarkers	127
Comment	127
Drug	128
Overview	128
Clinical trials	129
Biomarkers	130
Comment	130
Drug	131
Overview	131
Clinical trials	132
Biomarkers	132

Comment	132
Drug	133
Overview	133
Clinical trials	134
Biomarkers	134
Comment	135
Drug	135
Overview	135
Clinical trials	136
Biomarkers	136
Comment	137
Drug	137
Overview	137
Clinical trials	138
Biomarkers	139
Comment	139
Drug	140
Overview	140
Clinical trials	141
Biomarkers	142
Comment	142
Drug	142
Overview	142
Clinical trials	144
Biomarkers	145
Comment	146

Appendix	147
Shortlisted Phase II oncology drugs	147
Summary of fully profiled drugs	152
Abbreviations	155
References	160

Table of figures

Figure 1:	Cancer incidence segmented by type of cancer, 2010	25
Figure 2:	Geographical distribution of the incidence of all cancers, 2010	27
Figure 3:	Current pharmacological treatment options for cancer	29
Figure 4:	Total and average partnership deal values in oncology (\$m), 2001–11	41
Figure 5:	Upfront payments in oncology partnership deals (\$m), 2001–11	43
Figure 6:	Milestone payments in oncology partnership deals (\$m), 2001–11	45
Figure 7:	Commercialization deal between Astellas and Aveo	46
Figure 8:	Co-development and commercialization deal between Genentech and Array Biopharma	47
Figure 9:	Global licensing and research collaboration between Sanofi and Ascenta	48
Figure 10:	Co-development and commercialization deal between Allos and Mundipharma	49
Figure 11:	chemical structure	52
Figure 12:	chemical structure	58
Figure 13:	chemical structure	61
Figure 14:	chemical structure	72
Figure 15:	chemical structure	75
Figure 16:	chemical structure	77
Figure 17:	chemical structure	81
Figure 18:	chemical structure	86
Figure 19:	chemical structure	91
Figure 20:	chemical structure	98
Figure 21:	chemical structure	104
Figure 22:	chemical structure	112
Figure 23:	chemical structure	115
Figure 24:	chemical structure	118
Figure 25:	chemical structure	128
Figure 26:	chemical structure	133
Figure 27:	chemical structure	137
Figure 28:	chemical structure	143

Table of tables

Table 1:	Forecast of the worldwide global incidence of different cancers types, 2010–20	26
Table 2:	Forecast for the incidence of all cancers by geography, 2010–2020	28
Table 3:	Global cancer market share by geography (\$m), 2010	32
Table 4:	Global cancer market by drug class (\$m), 2010	33
Table 5:	Sales of leading brands in the global cancer market (\$m), 2010	34
Table 6:	Global cancer market sales forecast (\$m), 2010–16	35
Table 7:	Partnership deals by therapy area, 2001–11	37
Table 8:	Licensing deals by therapy area, 2001–11	38
Table 9:	Oncology partnership deals by deal subtype, 2001–11	39
Table 10:	Total and average partnership deal values in oncology (\$m), 2001–11	40
Table 11:	Upfront payments in oncology partnership deals (\$m), 2001–11	42
Table 12:	Milestone payments in oncology partnership deals (\$m), 2001–11	44
Table 13:	overview	50
Table 13:	clinical trials	51
Table 15:	overview	52
Table 16:	clinical trials (part 1)	54
Table 17:	clinical trials (part 2)	55
Table 18:	clinical trials (part 3)	56
Table 19:	overview	58
Table 20:	clinical trials	59
Table 21:	overview	61
Table 22:	clinical trials	62
Table 23:	overview	64
Table 24:	clinical trials	65
Table 25:	overview	66
Table 26:	clinical trials	67
Table 27:	overview	68
Table 28:	clinical trials	69
Table 29:	overview	70
Table 30:	clinical trials	71
Table 31:	overview	72
Table 32:	clinical trials	73
Table 33:	overview	74
Table 34:	clinical trials	75

Table 35: overview	76
Table 36: clinical trials	78
Table 37: overview	79
Table 38: clinical trials	80
Table 39: overview	81
Table 40: clinical trials	82
Table 41: overview	84
Table 42: overview	85
Table 43: clinical trials	87
Table 44: overview	88
Table 45: clinical trials (part 1)	89
Table 46: clinical trials (part 2)	90
Table 47: overview	91
Table 48: clinical trials	92
Table 49: overview	93
Table 50: clinical trials	94
Table 51: overview	94
Table 52: clinical trials	96
Table 53: overview	98
Table 54: clinical trials (part 1)	99
Table 55: clinical trials (part 2)	100
Table 56: clinical trials (part 3)	101
Table 57: clinical trials (part 4)	102
Table 58: overview	104
Table 59: clinical trials (part 1)	105
Table 60: clinical trials (part 2)	106
Table 61: clinical trials (part 3)	107
Table 62: clinical trials (part 4)	108
Table 63: overview	110
Table 64: clinical trials	111
Table 65: overview	112
Table 66: clinical trials (part 1)	113
Table 67: clinical trials (part 2)	114
Table 68: overview	115
Table 69: clinical trials	116
Table 70: overview	117

Table 71:	clinical trials	119
Table 72:	overview	120
Table 73:	clinical trials (part 1)	121
Table 74:	clinical trials (part 2)	122
Table 75:	clinical trials (part 3)	123
Table 76:	overview	124
Table 77:	clinical trials	125
Table 78:	overview	126
Table 79:	clinical trials	127
Table 80:	overview	128
Table 81:	clinical trials	129
Table 82:	overview	131
Table 83:	clinical trials	132
Table 84:	overview	133
Table 85:	clinical trials	134
Table 86:	overview	135
Table 87:	clinical trials	136
Table 88:	overview	137
Table 89:	clinical trials	138
Table 90:	overview	140
Table 91:	clinical trials	141
Table 92:	overview	142
Table 93:	clinical trials (part 1)	144
Table 94:	clinical trials (part 2)	145
Table 95:	Shortlisted Phase II oncology drugs (part 1)	147
Table 96:	Shortlisted Phase II oncology drugs (part 2)	148
Table 97:	Shortlisted Phase II oncology drugs (part 3)	149
Table 98:	Shortlisted Phase II oncology drugs (part 4)	150
Table 99:	Shortlisted Phase II oncology drugs (part 5)	151
Table 100:	Summary of fully profiled licensing opportunities (part 1)	152
Table 101:	Summary of fully profiled licensing opportunities (part 2)	153
Table 102:	Summary of fully profiled licensing opportunities (part 3)	154
Table 103:	Summary of fully profiled licensing opportunities (part 4)	155